The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Number of Participants With all Adverse Events (AEs)
Time frame: From Day 1 up to last visit (Up to 12 months)
Number of Participants With Post-Treatment Responses as Assessed Using Subject Diary Data
Time frame: From Day 1 up to Day 28
Participant's Pain Assessment Using Numeric Pain Scale (NPS) Immediately Post Treatment and 30 Minutes Post Treatment
Time frame: Immediately and 30 minutes after each treatment
Responder Rates Based on the Treating Investigator's Live Assessment of the GCWS at Rest at Months 3, 6, 9 and 12
Time frame: At Months 3, 6, 9 and 12
Responder Rates Based on the Treating Investigator's Live Assessment of the CSQS-CL at Rest at Months 3, 6, 9 and 12
Time frame: At Months 3, 6, 9 and 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.